Drugs / BBI-940
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07408089 | Feb 2026 → Feb 2029 expected | breast cancer | Boundless Bio, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBI-940 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07408089 ↗ |
| Modality | Small molecule | “Oral small molecule degrader targeting Kinesin.” NCT07408089 ↗ |
| Route | Oral | “BBI-940 is given orally in repeated 28-day cycles.” NCT07408089 ↗ |